Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Lung Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Adenocarcinoma 1

Interventions

Leucovorin 22Fluorouracil 22Paclitaxel 21Gemcitabine 21Docetaxel 21Capecitabine 21Irinotecan 16Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × vandetanib × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡